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Abstract
Background The combination of midazolam and droperi-
dol has proven superior to droperidol or olanzapine
monotherapy in the management of acute agitation in
emergency departments (EDs).
Objective This is the first economic analysis to evaluate
the cost–benefit and cost effectiveness of the midazolam–
droperidol combination compared with droperidol or
olanzapine for the management of acute agitation in EDs.
Methods This analysis used data derived from a ran-
domised, controlled, double-blind clinical trial conducted
in two metropolitan Australian EDs between October 2014
and August 2015. The economic evaluation was from the
perspective of Australian public hospital EDs. The main
outcomes included agitation management time and the
agitation-free time gained. Sensitivity analyses were
undertaken.
Results The midazolam–droperidol combination was the
least costly regimen (Australian dollars [AU$]46.25 per
patient) compared with the droperidol and olanzapine
groups (AU$92.18 and AU$110.45 per patient, respec-
tively). The main cost driver for all groups was the cost of
the labour required during the initial adequate sedation.
The combination afforded an additional 10–13 min of
mean agitation-free time gained, which can be translated to
additional savings of AU$31.24–42.60 per patient com-
pared with the droperidol and olanzapine groups. The
benefit–cost ratio for the midazolam–droperidol combina-
tion was 12.2:1.0, or AU$122,000 in total benefit for every
AU$10,000 spent on management of acute agitation. Sen-
sitivity analyses over key variables indicated these results
were robust.
Conclusions The midazolam–droperidol combination may
be a cost-saving and dominant cost-effective regimen for
the treatment of acute agitation in EDs as it is more
effective and less costly than either droperidol or olanza-
pine monotherapy.
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Key Points For Decision Makers
The combination of midazolam and droperidol is
more effective and cost saving than droperidol or
olanzapine monotherapy in managing acute agitation
in the emergency department (ED).
The rapid effect of the midazolam–droperidol
combination could allow clinical and security staff to
spend less time restraining agitated patients, leading
to a reduced burden on personnel requirements in
EDs.
1 Introduction
Aggression or acute agitation caused by alcohol or illicit
drug intoxication with or without underlying mental illness
is a common occurrence in emergency departments (EDs)
[1–3]. Patients presenting with acute agitation in the ED
often require more intensive resources for their manage-
ment than do general medical patients [4, 5].
The recommended standard approach to managing acute
agitation in EDs is early verbal de-escalation followed by
the use of sedative medications and mechanical restraint if
verbal de-escalation fails [6–8]. Existing guidelines rec-
ommend at least five staff (e.g. two nurses, one doctor and
two security staff) should be available during the process of
restraint and sedation to ensure the procedure can be per-
formed safely and effectively [1, 7–9]. Given the labour-
intensive nature of the management, a prolonged period of
agitation places substantial strain on the human resources
of EDs and is costly to the hospital.
Benzodiazepines (e.g. midazolam, diazepam) or
antipsychotics (e.g. droperidol, olanzapine) are commonly
used for sedation in EDs to manage acute agitation
[10–13]. A recent systematic review concluded that a
combination regimen (i.e. benzodiazepines and antipsy-
chotics in combination) is associated with more rapid
sedation and fewer adverse events (AEs) than benzodi-
azepine monotherapy [14]. While a number of trials have
demonstrated that antipsychotics are at least as effective as
benzodiazepine monotherapy [11, 13], clinical data com-
paring the use of antipsychotics alone versus combination
regimens are lacking.
A multicentre randomised controlled trial (RCT) com-
paring the efficacy and safety of the midazolam–droperidol
combination with that of droperidol or olanzapine
monotherapy was recently reported [15]. The trial indicated
that the midazolam–droperidol combination is superior to
both droperidol and olanzapine monotherapy and that
safety profiles are comparable. However, whether this
combination regimen is more cost saving is unknown. For
the purpose of this study, the primary analysis is a cost–
benefit analysis. The secondary analysis is a cost-effec-
tiveness analysis that explores the effectiveness (i.e. agi-
tation-free time gained) of the midazolam–droperidol
combination versus droperidol or olanzapine monotherapy
for the management of acute agitation in EDs.
2 Methods
2.1 Study Design, Setting and Population
This economic evaluation was conducted from the Aus-
tralian public hospital ED perspective. Clinical outcomes
and resource utilisation were obtained from an RCT [15]
(Australian and New Zealand Clinical Trials Registry
identifier: ACTRN12614000980639) undertaken in the ED
of two metropolitan public hospitals in Melbourne, Aus-
tralia, from October 2014 to August 2015.
Patients were eligible for inclusion in the trial if they
were aged 18–65 years and required intravenous sedation
for acute agitation. A total of 349 patients were randomised
to an intravenous bolus of midazolam 5 mg–droperidol
5 mg combination or droperidol 10 mg or olanzapine
10 mg [15]. Two additional doses were administered if
required: midazolam 5 mg, droperidol 5 mg or olanzapine
5 mg, respectively. If adequate sedation was not achieved
5 min after the two additional doses, additional open-label
sedative medication(s) could be administered at the doc-
tor’s discretion.
This economic analysis was approved by the Melbourne
Health Human Research Ethics Committees. Reporting of
this analysis followed the Consolidated Health Economic
Evaluation Reporting Standards (CHEERS) checklist [16].
2.2 Outcome Measurement
The clinical outcome was adequate sedation, which was
defined as a score\ 2 based on a 6-point, validated Acute
Arousal Scale [17] (5 = highly aroused, violent toward
self, others, or property; 4 = highly aroused and possibly
distressed or fearful; 3 = moderately aroused, agitated,
more vocal, unreasonable, or hostile; 2 = mildly aroused,
pacing, willing to talk reasonably; 1 = settled, minimal
agitation; 0 = asleep).
In the RCT, the time required to achieve the initial
adequate sedation, the need for and frequency of re-seda-
tion within 60 min after achieving the initial adequate
sedation and sedation AEs were assessed [15]. When a
patient required re-sedation within 60 min after achieving
the initial adequate sedation, frequency of re-sedation,
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mean duration of clinical and security staff attendance,
dose and medication used were recorded. Overall, 22
patients required re-sedation within 60 min after achieving
the initial adequate sedation. The mean duration of clinical
and security staff attendance for one re-sedation episode
was 27 min. A total of 14 patients experienced airway
obstruction: seven with the midazolam–droperidol combi-
nation, three with droperidol and four with olanzapine.
Two primary outcome measurements were used in the
current economic evaluation: agitation management time
(i.e. time required to achieve initial adequate seda-
tion ? number of re-sedations 9 27 min) (Table 1) and
the agitation-free time gained. In the RCT, the maximum
time required to manage an episode of agitation was
185 min (proximately[3 h); therefore, we assumed that all
episodes of agitation can be managed within 3.5 h (i.e.
210 min). For that reason, agitation-free time gained was
calculated as 210 min minus the agitation management
time for the patient.
2.3 Assumptions
The following assumptions were made when measuring the
cost of management:
1. The cost of consumables (e.g. intravenous line, tubing
and oxygen) were identical for all three regimens.
2. All patients required the attendance of five staff (one
ED doctor; two senior ED registered nurses [RNs]—
one grade 2 RN with at least 5 years of experience and
one grade 3 RN, usually a floor coordinator; and two
security staff) to administer the sedative medication
from initial drug administration until adequate sedation
and during each re-sedation episode.
3. If airway obstruction occurred, only one episode of
airway management was required throughout the
sedation period for each patient.
4. No additional pathology, imaging or monitoring tests
were required as a consequence of sedation.
2.4 Measurement of Costs
The costs of management related to the use of the sedative
medication, consumables and personnel to manage the
acute agitation and the airway; the savings resulted from
the decrease in human resource utilisation (i.e. agitation-
free time gained).
2.4.1 Cost of Management
A bottom-up approach was used to calculate the mean costs
by tracing the actual use of resources and medications for
each patient recruited [18]. Discounting was not applied
because of the short duration of the ED presentations. All
costs were expressed in Australian dollars (AU$) for the
financial year 2015–2016.
We took a conservative approach by focusing on the
cost of management incurred during the initial adequate
sedation, the re-sedation and the airway management. The
direct medical costs of managing agitation do not include
non-agitation management costs such as costs related to
other underlying medical or psychiatric problems and costs
for the entire ED length of stay (LOS). Estimated unit costs
used are listed in Table 2.
The costs per initial adequate sedation were categorised
as labour costs or medication costs. Labour costs were
calculated by multiplying the time required to achieve
initial adequate sedation by the sum of the average hourly
wages of five hospital staff involved in the sedation process
(see Sect. 2.3). The mean hourly wages of ED doctors with
different years of experience (varying from year 1 to 6),
and the mean hourly wages for grade 2 RNs (year 5–10)
were used. Hourly wages for security staff were obtained
from the hospital human resources department, hourly
wages for ED doctors were obtained from the Australian
Medical Association Victoria [19, 20] and hourly wages for
RNs were obtained from the Australian Nursing and
Midwifery Federation [21]. Medication costs were the
mean costs of medications to achieve initial adequate
Table 1 Mean agitation management time using midazolam–droperidol combination, droperidol or olanzapine monotherapy
Outcomes Mean agitation management time (SD), min
Midazolam–droperidol (n = 118) Droperidol (n = 111) Olanzapine (n = 120)
Sedated with no re-sedation 9.6 (14.7) 20.2 (25.7) 22.2 (30.1)
Sedated with one re-sedation 35 (7.0) 34 (0.7) 62 (24.8)
Sedated with two re-sedation – 74 (16.5) 83 (36.7)
Sedated with three re-sedation 92a – 88a
Overall 11.7 (17.3) 22.1 (27.1) 25.6 (33.0)
SD standard deviation
a Only one case with three re-sedation events within 60 min after initial sedation; actual time was reported and no SD could be calculated
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sedation, which included both study medications and other
open-label sedative medications. Medication acquisition
costs were obtained from the Australian Health Purchasing
Victoria Catalogue 2012-058 [22]. The doses administered
were rounded up and costed to the nearest vial size to
account for wastage.
The costs of sedation with re-sedation were calculated
by adding the cost of initial adequate sedation and the cost
of re-sedation according to the number of re-sedations
required. The cost per re-sedation was calculated by adding
the labour costs and the medication costs associated with
one re-sedation. The labour cost was calculated by multi-
plying the mean time required to re-sedate the patient (i.e.
27 min) by the sum of the average hourly wages of five
hospital staff. Adjusted medication costs were based on the
probabilities of each medication used for re-sedation within
60 min after achieving initial adequate sedation.
For patients requiring airway management, additional
costs were added to the total cost of managing the acute
agitation. The added cost of one airway management was
the sum of the labour cost and the cost of consumables [i.e.
oropharyngeal airway (OPA) or nasopharyngeal airway
(NPA)]. The labour cost was calculated by multiplying the
estimated time for one airway management (i.e. 30 min) by
the sum of the average hourly rate of one ED doctor and
one grade 3 RN. The time per airway management was
estimated based on the experiential knowledge of the ED
consultants and senior ED nurses, who have extensive
experience in managing airway compromise requiring air-
way adjuncts.
2.5 Cost–Benefit Analysis
As cost–benefit analyses express both inputs and conse-
quences of different regimens in monetary units [23],
agitation-free time gained was multiplied with total cost of
the response team per minute (i.e. AU$2.84/min) to mea-
sure the economic benefits gained. Benefit–cost ratios for
all three sedation regimens were calculated by dividing the
economic benefits by the management costs.
Table 2 Estimated unit costs
Items Description Unit costs (AU$)
Labour costs ED doctor (per minute) 0.84
ED RN grade 2 (per minute) 0.52
ED RN grade 3 (per minute) 0.59
Security staff (per minute) 0.44
Total cost of response team (per minute)a 2.84
Medication costs Midazolam 5 mg/5 ml 0.23
Droperidol 2.5 mg/ml 4.54
Olanzapine 10 mg 20.22
Water for injection 10 ml 0.12
Cost of re-sedation within 60 min after achieving
initial adequate sedation
ED doctor time (27 minb) 22.97
Two security staff time (27 minb) 23.76
One grade 2 RN (27 minb) 14.24
One grade 3 RN (27 minb) 15.98
Adjusted medication costsc 6.46
Total cost of one re-sedation 83.41
Cost of airway management ED doctor time (30 min) 25.32
Grade 3 RN time (30 min) 17.62
Consumable costs (NPA, OPA) 4.63d
Total cost of one airway management 47.56
Costs are presented in Australian dollars, year 2015–2016 values
ED emergency department, NPA nasopharyngeal airways, OPA oropharyngeal airways, RN registered nurse
a Response team consists of one ED doctor, one ED RN grade 2, one RN grade 3 (floor coordinator) and two security staff
b Average time for one security alert for a re-sedation episode
c Adjusted medication costs are calculated based on the probabilities of each medication (midazolam, droperidol, olanzapine, ketamine) being
used for re-sedation within 60 min
d The mean cost of the unit price for NPA and OPA
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2.6 Cost-Effectiveness Analysis
In this study, the cost-effectiveness analysis compared dif-
ferent sedation regimens in terms of cost per minute of agi-
tation-free time gained. The incremental cost-effectiveness
ratio (ICER) is the difference in the cost of management
between the comparators (e.g. midazolam–droperidol and
droperidol) divided by the difference in their effectiveness
(i.e. agitation-free time gained). A positive ICER implies the
sedation regimen increased agitation-free time gained at a
certain cost; the ICER will be important for policy makers to
make decisions based on the willingness-to-pay value [24].
Whilst a negative numerator (cheaper cost) and a positive
denominator (e.g. more agitation-free time gained) imply the
intervention is more effective at a lower cost (i.e. a dominant
strategy), the ICER will not be calculated [24, 25].
2.7 Sensitivity Analyses
The robustness of the result was assessed using both one-
way and two-way sensitivity analyses to examine the
uncertainty surrounding key variables. These analyses
included changes in the drug-acquisition costs, mean initial
adequate sedation medication and labour costs, mean
duration of staff attendance during re-sedation, probabili-
ties of the need for re-sedation, costs of consumables, and
duration of airway management. The variables and ranges
of variation are shown in Table 3. All analyses were per-
formed using TreeAge Pro 2015, R1.0. (TreeAge Software,
Williamstown, MA, USA).
Two-way sensitivity analysis was performed to examine
the worst- and the best-case scenarios based on the varia-
tion of the mean agitation-free time gained and the mean
total management costs. An alternative scenario, with the
ideal number of staff members (i.e. seven staff) involved in
both initial sedation and re-sedation was also evaluated.
2.8 Statistical Analysis
The sample size was calculated based on the primary end-
points of theRCT rather than the economic evaluation [15]. In
the RCT, of the 361 patients enrolled, only a small number
(12; 3% of the total) were excluded for either missing the
primary endpoint or for repeatedenrolment.Hence, only cases
with complete data were included in the analysis, which
shouldhave little impact on the accuracy of the results.As cost
data distribution are positively skewed [23, 26], some studies
reported median and interquartile range values [27, 28].
However, the provision of information about mean costs is
more helpful to policymakers,who require information on the
total cost of implementing a strategy bymultiplying the mean
costs by the total number of patients [26]. Therefore, mean
costs and 95% confidence intervals (CIs) are reported.
3 Results
3.1 Base-Case Analysis
The midazolam–droperidol combination was found to be
more cost saving than droperidol or olanzapine
monotherapy; it is also a dominant regimen, i.e. it was
cheaper and more effective. The overall mean cost of
management with the midazolam–droperidol combination
was AU$46.25 (95% CI 36.77–55.74) per patient compared
with AU$92.18 (95% CI 76.66–107.70) per patient with
droperidol and AU$110.45 (95% CI 91.51–129.39) per
patient with olanzapine (Table 4). Despite the higher costs
of re-sedation and airway management with the midazo-
lam–droperidol combination, the overall mean cost of this
combination regimen was 50 and 58% lower than that of
droperidol or olanzapine monotherapy, respectively
(Table 4). The main cost driver for all groups was the
labour costs required during the initial adequate sedation
(Fig. 1).
In terms of improved effectiveness, the mean agitation-
free time gained with the midazolam–droperidol combi-
nation was 199 (95% CI 196–202) min compared with 188
(95% CI 183–193) min with droperidol and 184 (95% CI
179–190) min with olanzapine (Table 6). This additional
agitation-free time gained resulted in additional economic
benefits of AU$31.24 and AU$42.60 per patient (Table 5),
respectively.
Overall, the total economic benefits of the midazolam–
droperidol combination compared with droperidol and
olanzapine was AU$77.17 and AU$106.80 per patient,
respectively. The net benefit–cost ratio for the midazolam–
droperidol combination was 12.2:1.0 (Table 5), equivalent
to AU$122,000 cost savings for every AU$10,000 spent on
the management of acute agitation with this combination.
3.2 Sensitivity Analyses
One-way sensitivity analyses indicated that the conclusion
of this evaluation was not sensitive to the variation of all
the parameters at the range shown in Table 3. For two-way
sensitivity and alternative scenario analysis (Table 7), the
midazolam–droperidol combination remained the most
cost-saving (Table 5) and the dominant regimen (Table 6).
4 Discussion
This is the first analysis to evaluate the cost–benefit and
cost effectiveness of managing acute agitation in EDs with
a midazolam–droperidol combination compared with either
droperidol or olanzapine monotherapy. Importantly,
because much less time is required to manage one acute
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agitation presentation, the midazolam–droperidol combi-
nation was more effective and cost saving than droperidol
and olanzapine monotherapies. This provides pivotal
information to guide the use of these regimens in the ED
setting for the management of acute agitation. Sensitivity
analyses confirmed the robustness of the results across a
broad range of variations.
In a tertiary-care ED with approximately 450 episodes
of sedation for acute agitation (security database, unpub-
lished data, based on the experience of the Royal Mel-
bourne Hospital in 2014), the total annual mean cost to
manage these patients would be approximately AU$21,000
with the midazolam–droperidol combination compared
with nearly AU$42,000 with droperidol and AU$50,000
with olanzapine. Furthermore, as the midazolam–
droperidol combination increased the agitation-free time
gained by approximately 50%, this will result in further
cost savings of AU$14,058 and AU$19,170, respectively.
Thus, the midazolam–droperidol combination could gen-
erate a total annual cost savings of nearly AU$35,000 and
AU$48,000, respectively.
In addition to the benefit of cost savings, using the
midazolam–droperidol combination was also associated
with additional agitation-free time gained. The published
literature on agitation in the ED reports that these episodes
are more likely to occur in the evening or overnight, which
coincides with periods of minimal or reduced staffing
[1, 29]. Liberating a team of healthcare staff for that
amount of time would have the potential to enhance ED
patient flow. In a busy overnight shift, where it is possible
Table 3 Variation range for variables investigated in one-way sensitivity analyses
Variables Base case Variation range Source of range
Low High
Cost of midazolam 5 mg 0.23 0.02 0.44 Base case value ±90%
Cost of droperidol 2.5 mg 4.54 0.45 8.60 Base case value ±90%
Cost of olanzapine 10 mg 20.22 2.02 38.40 Base case value ±90%
Mean initial adequate sedation medication cost
Midazolam–droperidol 9.74 9.24 10.24 95% CI of the mean value
Droperidol 27.47 25.66 29.27 95% CI of the mean value
Olanzapine 35.30 32.84 37.75 95% CI of the mean value
Mean initial adequate sedation labour cost
Midazolam–droperidol 27.35 19.82 34.87 95% CI of the mean value
Droperidol 57.43 43.83 71.02 95% CI of the mean value
Olanzapine 63.17 47.88 78.45 95% CI of the mean value
Mean duration of clinical staff attendance during re-sedation (min) 27 11.6 42.4 ±SD (15.4 min)
Probabilities of sedated with no re-sedation (%)
Midazolam–droperidol 94.1 89.8 98.3 95% CI of the base case
Droperidol 95.5 91.6 99.3 95% CI of the base case
Olanzapine 91.7 86.7 96.6 95% CI of the base case
Probabilities of sedated with one re-sedation (%)
Midazolam–droperidol 5.1 1.1 9.0 95% CI of the base case
Droperidol 1.8 0a 4.2 95% CI of the base case
Olanzapine 5.0 1.1 8.9 95% CI of the base case
Probabilities of sedated with two re-sedation (%)
Midazolam–droperidol 0 0 30 Base-case value ?30%b
Droperidol 2.7 0a 5.7 95% CI of the base case
Olanzapine 2.5 0a 5.3 95% CI of the base case
Duration of airway management (min) 30 15 45 Base-case value ±50%
Cost of consumables for airway management 4.63 2.32 9.26 Base-case value ±50%
Costs are presented in Australian dollars, year 2015–2016 values
CI confidence interval, RCT randomised controlled trial, SD standard deviation
a Given the negative values for the lower bound of the 95% CI, zero was used to enable modelling
b No case was observed in the RCT and 30% was used to enable modelling
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to have up to eight episodes of acute agitation (Royal
Melbourne Hospital security database, unpublished data,
based on the experience of the Royal Melbourne Hospital
in 2014), using the midazolam–droperidol combination to
manage these patients will amount to a substantial decrease
in staff workload.
The cost-effectiveness analysis also revealed that the
midazolam–droperidol combination is the dominant regi-
men, being less costly and more effective than the other
two monotherapy regimens. Decision making should be
straightforward. Hence, the ICER is of little value in this
situation because the additional gain is not obtained with
additional costs.
Despite the resource implications, only one published
cost-minimisation analysis has evaluated the costs of
managing acute agitation in the ED [27]. However, that
study did not consider the differences in frequency of re-
sedation within 60 min and AE rates between the
droperidol and the midazolam regimens. Consequently,
direct comparison is not possible.
Our estimates of labour costs were built on the
assumption that three ED clinicians and two security staff
would attend a security alert during both an initial and a re-
sedation episode. Ideally, seven staff should be available
during the process of restraint and sedation: one security
staff member for each limb and one senior ED nurse for the
head (to prevent the patient from biting and to ensure the
patient’s airway is not compromised), and another ED
nurse to prepare medication for the ED doctor to administer
[7]. In situations involving seven staff, this would further
add to the economic advantage of using the midazolam–
droperidol combination.
The current evaluation suggests that airway obstruction
had limited impact on resource utilisation because of the
overall low rate of occurrence. Midazolam is associated
with an increased risk of respiratory complications that
Table 4 Mean costs of management using midazolam–droperidol combination, droperidol or olanzapine monotherapy
Outcomes at time
points
Midazolam–droperidol Droperidol Olanzapine
Proportion
(%)
Cost/pt Proportional
costa
Proportion
(%)
Cost/pt Proportional
costa
Proportion
(%)
Cost/pt Proportional
costa
Sedated with no re-sedation
No airway
obstruction
89.0 37.08 33.00 92.8 84.90 78.78 90.0 98.47 88.62
Airway
obstruction
5.1 84.64 4.30 2.7 132.46 3.58 1.7 146.03 2.43
Sedated with one re-sedation
No airway
obstruction
4.3 120.31 5.10 1.8 168.13 3.03 4.2 181.70 7.57
Airway
obstruction
0.8 167.87 1.42 0 215.69 0 0.8 229.26 1.91
Sedated with two re-sedation
No airway
obstruction
0 203.53 0 2.7 251.35 6.79 2.5 264.92 6.62
Airway
obstruction
0 251.09 0 0 298.91 0 0 312.48 0
Sedated with three re-sedation
No airway
obstruction
0.8 286.76 2.43 0 334.58 0 0 348.15 0
Airway
obstruction
0 334.32 0 0 382.14 0 0.8 395.71 3.30
Mean (95% CI)
costs of
management per
pt
46.25
(36.77–55.74)
92.18
(76.66–107.70)
110.45
(91.51–129.39)
Costs are presented in Australian dollars, year 2015–2016 values
CI confidence interval, pt patient
a The cost per patient was determined within each outcome, then multiplied by the proportion of patients, for the eight possible outcomes to get
the proportional cost
b The proportional costs for each outcome were summed to give the mean cost per patient for each regimen
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may lead to intubation [10, 13], whereas droperidol raises
concerns of QT prolongation and Torsades de Pointes
(TdP) [30]. It was not possible to estimate the impact of
intubation and TdP in the current within-trial analysis as no
patient experienced these AEs in the RCT [15]. As the
midazolam–droperidol combination reduced the need for
high-dose midazolam or droperidol monotherapy, and
subsequently reduced the risk of these severe AEs, the rare
incidence of these AEs and the associated costs were
unlikely to change the conclusions of this study. Similarly,
other minor AEs such as hypotension and oxygen desatu-
ration were not considered in this evaluation because those
AEs were assumed to be self-limiting and would not have a
significant impact on resource utilisation.
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Table 5 Results of two-way analyses (base-, worst- and best-case scenario) for cost–benefit analysis
Scenario Mean costs of
management
per patient
Economic benefits Incremental economic
benefits
Benefit–cost
ratio
Base casea
Midazolam–droperidol 46.25 (36.77–55.74) 565.16 (556.64–573.68) – 12.2:1.0
Droperidol 92.18 (76.66–107.70) 533.92 (519.72–548.12) –31.24 5.8:1.0
Olanzapine 110.45 (91.51–129.39) 522.56 (508.36–539.60) –42.60 4.7:1.0
Worst case
Midazolam–droperidol 55.74 556.64 – 10.0:1.0
Droperidol 76.66 548.12 –8.52 7.2:1.0
Olanzapine 91.51 539.60 –17.04 5.9:1.0
Best case
Midazolam–droperidol 36.77 573.68 – 15.6:1.0
Droperidol 107.70 519.72 –53.96 4.8:1.0
Olanzapine 129.39 508.36 –65.32 3.9:1.0
Costs are presented in Australian dollars, year 2015–2016 values
Economic benefits = mean agitation-free time gained (min) 9 total cost of response team (AU$2.84) per minute; negative sign indicates that the
midazolam–droperidol combination generated greater economic benefits
a Mean (95% confidence interval)
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We acknowledge several limitations in this study. First,
the results of this study can only be interpreted in the
context of acutely agitated patients in the ED setting, and
the results cannot be generalised to psychiatric inpatients.
Furthermore, estimates of the mean costs of management
were based on data from only one RCT, and more eco-
nomic evaluations on the cost–benefit and cost effective-
ness of other sedative regimens for the management of
acute agitation in EDs are warranted.
To understand the immediate impact of the combination
regimen, our evaluation was confined to the initial ade-
quate sedation stage. Thus, hospitalisation costs for the
entire ED LOS were not considered. However, in the RCT
[15], we found that the ED LOS was not sensitive to the
choice of sedation regimen. Patient disposition can be
influenced by other non-sedation-related factors, including
underlying medical comorbidities, availability of inpatient
beds, time of the day, etc. [31]. Therefore, the exclusion of
hospitalisation costs for the entire ED LOS would afford a
more accurate measure of the efficiency of the different
sedation regimens in managing the acute agitation.
Finally, the re-sedation rate after 60 min was not
included in this analysis because the need for further
sedation after 60 min is subject to a patient’s risk of violent
behaviour after the initial adequate sedation. Prolonged
sedation is not the goal of acute agitation management.
Table 6 Results of two-way analyses (base-, worst- and best-case scenario) for cost-effectiveness analysis
Scenario Mean costs of management
per patient
Incremental
cost
Effectiveness (mean agitation-free
time gained, min)
Incremental
effectiveness (min)
ICER
Base casea
Midazolam–
droperidol
46.25 (36.77–55.74) – 199 (196–202) – Dominant
Droperidol 92.18 (76.66–107.70) 45.93 188 (183–193) –11 Dominated
Olanzapine 110.45 (91.51–129.39) 64.20 184 (179–190) –15 Dominated
Worst case
Midazolam–
droperidol
55.74 – 196 – Dominant
Droperidol 76.66 20.92 193 –3 Dominated
Olanzapine 91.51 35.77 190 –6 Dominated
Best case
Midazolam–
droperidol
36.77 – 202 – Dominant
Droperidol 107.70 70.93 183 –19 Dominated
Olanzapine 129.39 92.62 179 –23 Dominated
Costs are presented in Australian dollars, year 2015–2016 values
ICER incremental cost-effectiveness ratio
a Mean (95% confidence interval)
Table 7 Results of alternative scenario analysis
Alternative
scenarioa
Mean cost of
management per patient
Incremental
cost
Effectivenessb Incremental
effectiveness
(min)
Economic
benefits
Economic
benefits
difference
Benefit-
cost
ratio
ICER
Midazolam–
droperidol
56.63 (44.47–68.80) – 199 (196–202) – 742.27 – 13.1:1 Dominant
Droperidol 111.87 (91.89–131.85) 55.24 188 (183–193) –11 701.24 –41.03 6.3:1 Dominated
Olanzapine 133.21 (109.05–157.37) 76.58 184 (179–190) –15 686.32 –55.95 5.2:1 Dominated
Costs are presented in Australian dollars, year 2015–2016 values; figures in parentheses are 95% confidence intervals
Economic benefits = mean agitation-free time gained (min) 9 total cost of response team (AU$3.73) per minute; negative sign denotes the
midazolam–droperidol combination generated greater economic benefits
ICER incremental cost-effectiveness ratio, RN registered nurse
a Seven staff case scenario (one doctor, one grade 3 RN, one grade 2 RN, and four security staff). Total cost of the response team: AU$3.73/min
b Mean agitation-free time gained, min
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However, taking such costs into account would likely have
no important influence on the cost savings of the midazo-
lam–droperidol combination because the cost of re-seda-
tion was not the main cost driver.
5 Conclusions
The midazolam–droperidol combination may be more
effective and less costly than both droperidol and olanza-
pine monotherapy. This study provides support, from an
optimal use of resource perspective, for the use of the
midazolam–droperidol combination over droperidol or
olanzapine monotherapy in the management of acute agi-
tation in the ED. The rapid sedative effect of the midazo-
lam–droperidol combination could allow clinical and
security staff to spend less time restraining agitated patients
and lead to substantial cost savings and freeing up of
precious ED personnel for other emergency cases.
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